1. A PHASE I TRIAL OF TARGETED IMMUNOTHERAPY WITH DARATUMUMAB FOLLOWING MYELOABLATIVE TOTAL BODY IRRADIATION (TBI)-BASED CONDITIONING AND ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATON IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS WITH HIGH-RISK T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND LYMPHOMA (T- ALL/T-LLy) (ALLO-T-DART) (IND 159396): A PTCTC FACILITATED STUDY. (October 2022) Authors: Quigg, T.; Flower, A.; Teachey, D.; Lim, M.; Chu, Y.; Harrison, L.; Morris, E.; Gardenswartz, A.; Hochberg, J.; Ozkaynak, M.; Rosenblum, J.; Milner, J.; Pehlivan, K.; Levendoglu-Tugal, O.; Fabricatore, S.; Wolownik, K.; Ayello, J.; Rigot, O.; Klejmont, L.; Campbell, M. Journal: Leukemia research Issue: Volume 121(2022)Supplement Page Start: S71 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗